title: ACE inhibition scintigraphy in the management of hypertension in children.
abstract: Angiotensin converting enzyme (ACE) inhibition scintirenography was performed to help establish the diagnosis and plan treatment of renovascular hypertension (RVH) in 57 hypertensive pediatric patients, 33 infants and 24 children older than 1 year. In 16 of 33 hypertensive infants, ACE inhibition scintirenography established the diagnosis of RVH from renal ischemia (due to aortic or renal arterial thrombi). Two scintigraphic criteria were used for the diagnosis of RVH: criterion I, ischemic and damaged kidney (a non-functioning kidney on or off ACE inhibition) and criterion II, ischemic but not damaged kidney (ACE inhibition induced deterioration of function of the kidney). When criterion I was present and the contralateral kidney was normal, ACE inhibitors could be used for treatment of hypertension without deterioration of renal function; kidneys satisfying criterion I eventually involuted or manifested growth arrest and frequently caused persistent RVH, even after resolution of the thrombus, requiring nephrectomy. When criterion II was present bilaterally, or it was associated with criterion I contralaterally, the use of antihypertensive drugs other than ACE inhibitors was necessary in order to prevent renal insufficiency or failure from ACE inhibitors. However, kidneys with criterion II showed normal growth and, following retraction or dissolution of the aortic thrombus, hypertension resolved. In 2 of 24 hypertensive children older than 1 year, the test was diagnostic of branch renal artery stenosis; RVH was cured by selective angioplasty. ACE inhibition scintirenography is useful in the evaluation and planning of treatment in children with hypertension and may predict the outcome of therapy and ultimate renal function.
authors.affiliation: Department of Pediatrics (Nephrology), University of Miami School of Medicine, Jackson Memorial Hospital, Florida 33101, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Chandar
authors.forename: G N
authors.initials: GN
authors.lastname: Sfakianakis
authors.forename: G E
authors.initials: GE
authors.lastname: Zilleruelo
authors.forename: J J
authors.initials: JJ
authors.lastname: Guerra
authors.forename: M F
authors.initials: MF
authors.lastname: Georgiou
authors.forename: C L
authors.initials: CL
authors.lastname: Abitbol
authors.forename: B S
authors.initials: BS
authors.lastname: Montane
authors.forename: J
authors.initials: J
authors.lastname: Strauss
mesh_terms: D000293:Adolescent; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D002216:Captopril / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D006801:Humans; D006978:Hypertension, Renovascular / Q000000981:diagnostic imaging* / Q000628:therapy*; D007022:Hypotension / Q000139:chemically induced / Q000628:therapy; D007223:Infant; D007668:Kidney / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D012189:Retrospective Studies; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril